AMBER FLYNN: Open Payments
NPI 1235795246 · INMAN, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 24 payments from 14 companies in 2025. Trend: 2023 $658 · 2024 $596 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| Glaukos Corporation | 2 | $72 |
| Lilly USA, LLC | 3 | $62 |
| Novo Nordisk Inc | 4 | $57 |
| Astellas Pharma US Inc | 2 | $53 |
| ABBVIE INC. | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Amgen Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $23 |
| PFIZER INC. | 1 | $22 |
Products named: iDoseTR, Veozah, VRAYLAR, MOUNJARO, OTEZLA, Ozempic, Rybelsus, INSPIRE.
Industry payments across SC — which companies pay providers there.
